地西他滨治疗血液髓系肿瘤的临床现状
摘要
随着对肿瘤表观遗传学的深入研究，发现DNA甲基化异常在肿瘤的发生和转化中起着重要作用。这提示抑制DNA甲基化，激活沉默失活的基因，可作为肿瘤治疗的一个新靶点。研究发现，地西他滨（DAC）主要通过抑制DNA甲基化转移酶生物学活性实现去甲基化作用，从而活化抑癌基因，并且诱导细胞分化。本文总结了地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床现状，试图找出更好的方案。
出处
《中国伤残医学》
2014年第8期294-295,共2页
Chinese Journal of Trauma and Disability Medicine
参考文献24
-
1Santos FP, Kanrarjian H, Garcia-Manero G, et al. Dcitabine in the treatment of myelodysplastic syndrome[J]. Expert Rev Anti-cancer Ther, 2010, 10:9-22.
-
2Zagnel V, Io Re G, Marotta G, et al. 5- aza-2'deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndrome[J]. Leukemia, 1993, 7(Suppl 1):30-35.
-
3Wijermans P, Krulder JW, Huijgens PC, et al. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome[J]. Lekukemia, 1997, l 1:1 5.
-
4Wijermans P, Lubhert M, Verhoef G, et al. Low dose 5-Aza-2'- deoxycytidine, a DNA hyomethylating agent, for the treatment of high-risk myelodysplastic syndrome:A muhicenter phase II study in elderly patients[J]. J Clin Oncol, 2000, 18(5):95- 962.
-
5Kantarjian HM, O' Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome : comparison with historical experie- nce[J]. Cancer, 2007, 109(6):1133-1137.
-
6Lubbert M, Sueiu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome(MDS) ineligible for intensive chemotherapy: final results of the randomized phase IH study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J]. J Clin Oncol, 201 I, 29(15):1987-1996.
-
7Qin T, Castoro R, El AS, et al. Muhieenter study of resistance to dieitabine in the myelodysplastic syndrome[J]. PloA One, 2011, 6 (8):23372-23382.
-
8Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a rando- mized study of 3 schedules of low-dose decitabine in higher risk myelodysp]astie syndrome and chronic myelomonocytie leukemia[J]. Biood, 2007, 109:52-57.
-
9Steensma D P, Baer M R, Slack J L, et al. Multieenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes:the sltemative dosing for outpatient treatment(ADOPT) trial[J]. J Clin Oneol, 2009, 27(23):3842-3848.
-
10Lee J H, Jang J H, Park J, et al. A prospective multicenter study of dicitabine treatment in Korean patients with myelodysplastic syndrome[J]. Haematologica, 2011, 96(10):1441- 1447.
-
1涂真,唐培金,邓显忠.前列腺肉瘤的临床现状[J].临床泌尿外科杂志,2016,31(6):579-583. 被引量：3
-
2张育明,段芳龄,吴醒民.胰腺癌科研及临床现状[J].胃肠病学和肝病学杂志,1995,4(2):93-96.
-
3沈立杰.胆囊癌的临床现状[J].医学信息（下旬刊）,2009(5):75-76.
-
4刘佳,肖镇.急性白血病化疗后院内感染临床现状[J].临床医药实践,2015,24(2):126-129. 被引量：1
-
5秦新裕,刘凤林.早期胃癌及其临床现状[J].中国实用外科杂志,2007,27(11):857-859. 被引量：11
-
6王栋,张维铭.DNA甲基化异常与肿瘤发生的研究[J].三明学院学报,2002,20(4):40-44. 被引量：2
-
7杨涌,司勇锋.鼻咽癌远处转移的临床现状[J].健康之路,2015,0(10):68-69.
-
8赵向前,赵霖,冯玉泉.DNA甲基化异常与肿瘤[J].肿瘤防治研究,1999,26(2):152-154. 被引量：1
-
9肖文华,刘为纹.DNA甲基化异常与肿瘤研究现状[J].肿瘤,1995,15(3):297-300. 被引量：1
-
10王旭,马莉,苏克举,曹洪明,何华,李薇.地西他滨单药及联合其他药物在实体肿瘤治疗中应用的研究进展[J].吉林大学学报（医学版）,2015,41(4):870-873.
